The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders
- PMID: 23659216
- DOI: 10.1517/17460441.2013.796926
The design and discovery of T-type calcium channel inhibitors for the treatment of central nervous system disorders
Abstract
Introduction: Neuronal T-type calcium channels (T-type channels) are expressed throughout the central nervous system (CNS), regulating neuronal excitability. T-type channels in the CNS are involved in various neurophysiological and pathophysiological states, and thus have become a promising therapeutic target.
Areas covered: This article discusses T-type channel-related CNS disorders such as epilepsy, neuropathic pain, insomnia and tremor disorders including Parkinson's disease. In addition, the article reviews T-type channel inhibitors showing efficacy in animal models in such CNS disorders, with a focus on classical T-type channel inhibitors with limited specificity for T-type channels as well as novel inhibitors with high specificity. Furthermore, the article also presents and discusses the next generation of T-type channel inhibitor discovery, virtual as well as screening and high-throughput screening techniques.
Expert opinion: Although T-type channel-related CNS disorders seem to be diverse, it converges into the one major cause - abnormal hyperactivity of neurons. T-type channel-specific inhibitors could thus be commonly applied for the treatment of such CNS disorders regardless of the complexity of individual disorder. Structural information of inhibitor-binding sites would facilitate the discovery of the next generation of T-type channel-specific inhibitors by stimulating structure-based rational drug designs.
Similar articles
-
Recent patents on calcium channel blockers: emphasis on CNS diseases.Expert Opin Ther Pat. 2014 Sep;24(9):959-77. doi: 10.1517/13543776.2014.940892. Expert Opin Ther Pat. 2014. PMID: 25118673 Review.
-
Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats.Pharmacol Biochem Behav. 2011 Feb;97(4):656-9. doi: 10.1016/j.pbb.2010.11.014. Epub 2010 Nov 26. Pharmacol Biochem Behav. 2011. PMID: 21112351
-
Regulation of neuronal T-type calcium channels.Trends Pharmacol Sci. 2009 Jan;30(1):32-40. doi: 10.1016/j.tips.2008.10.004. Epub 2008 Nov 29. Trends Pharmacol Sci. 2009. PMID: 19042038 Review.
-
Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.J Med Chem. 2008 Oct 23;51(20):6471-7. doi: 10.1021/jm800830n. Epub 2008 Sep 26. J Med Chem. 2008. PMID: 18817368
-
T-type Ca2+ channels as therapeutic targets in the nervous system.Curr Opin Pharmacol. 2008 Feb;8(1):33-41. doi: 10.1016/j.coph.2007.12.003. Epub 2008 Jan 18. Curr Opin Pharmacol. 2008. PMID: 18203662 Review.
Cited by
-
Inhibition of human N- and T-type calcium channels by an ortho-phenoxyanilide derivative, MONIRO-1.Br J Pharmacol. 2018 Jun;175(12):2284-2295. doi: 10.1111/bph.13910. Epub 2017 Jul 21. Br J Pharmacol. 2018. PMID: 28608537 Free PMC article.
-
Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.Psychopharmacology (Berl). 2018 Nov;235(11):3339-3350. doi: 10.1007/s00213-018-5040-3. Epub 2018 Sep 24. Psychopharmacology (Berl). 2018. PMID: 30251162
-
Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues.RSC Med Chem. 2024 Jan 31;15(3):916-936. doi: 10.1039/d3md00714f. eCollection 2024 Mar 20. RSC Med Chem. 2024. PMID: 38516585 Free PMC article.
-
Isoprenylated Flavonoids as Cav3.1 Low Voltage-Gated Ca2+ Channel Inhibitors from Salvia digitaloides.Nat Prod Bioprospect. 2021 Dec;11(6):671-678. doi: 10.1007/s13659-021-00307-y. Epub 2021 Apr 24. Nat Prod Bioprospect. 2021. PMID: 33893991 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources